Any 0 3 0 3 O
investigational 4 19 4 19 B-treatment
drug 20 24 20 24 I-treatment
being 25 30 25 30 O
administered 31 43 31 43 O
during 44 50 44 50 O
the 51 54 51 54 O
study 55 60 55 60 O

Extreme 0 7 61 68 O
hyperleukocytosis 8 25 69 86 O
, 25 26 86 87 O
white 27 32 88 93 B-clinical_variable
blood 33 38 94 99 I-clinical_variable
cell 39 43 100 104 I-clinical_variable
( 44 45 105 106 I-clinical_variable
WBC 45 48 106 109 I-clinical_variable
) 48 49 109 110 I-clinical_variable
counts 50 56 111 117 I-clinical_variable
over 57 61 118 122 O
200 62 65 123 126 B-lower_bound
x 66 67 127 128 I-lower_bound
109 68 71 129 132 I-lower_bound
/ 71 72 132 133 I-lower_bound
L 72 73 133 134 I-lower_bound
( 74 75 135 136 I-lower_bound
200,000 75 82 136 143 I-lower_bound
/ 82 83 143 144 I-lower_bound
microL 83 89 144 150 I-lower_bound
) 89 90 150 151 I-lower_bound
at 91 93 152 154 O
the 94 97 155 158 O
time 98 102 159 163 O
of 103 105 164 166 O
enrollment 106 116 167 177 O

History 0 7 178 185 O
of 8 10 186 188 O
allergy 11 18 189 196 O
to 19 21 197 199 O
apixaban 22 30 200 208 B-allergy_name
or 31 33 209 211 O
Factor 34 40 212 218 B-allergy_name
Xa 41 43 219 221 I-allergy_name
inhibitors 44 54 222 232 I-allergy_name

History 0 7 233 240 O
of 8 10 241 243 O
any 11 14 244 247 O
significant 15 26 248 259 O
drug 27 31 260 264 O
allergy 32 39 265 272 O
( 40 41 273 274 O
such 41 45 274 278 O
as 46 48 279 281 O
anaphylaxis 49 60 282 293 B-allergy_name
or 61 63 294 296 O
hepatotoxicity 64 78 297 311 B-allergy_name

International 0 13 312 325 B-clinical_variable
normalized 14 24 326 336 I-clinical_variable
ratio 25 30 337 342 I-clinical_variable
( 31 32 343 344 I-clinical_variable
INR 32 35 344 347 I-clinical_variable
) 35 36 347 348 I-clinical_variable
> 37 38 349 350 O
1.4 39 42 351 354 B-lower_bound
and 43 46 355 358 O
activated 47 56 359 368 B-clinical_variable
partial 57 64 369 376 I-clinical_variable
thromboplastin 65 79 377 391 I-clinical_variable
time 80 84 392 396 I-clinical_variable
( 85 86 397 398 I-clinical_variable
aPTT 86 90 398 402 I-clinical_variable
) 90 91 402 403 I-clinical_variable
> 92 93 404 405 O
3 94 95 406 407 B-lower_bound
seconds 96 103 408 415 I-lower_bound
above 104 109 416 421 I-lower_bound
the 110 113 422 425 I-lower_bound
upper 114 119 426 431 I-lower_bound
limit 120 125 432 437 I-lower_bound
of 126 128 438 440 I-lower_bound
normal 129 135 441 447 I-lower_bound
for 136 139 448 451 O
age 140 143 452 455 B-age
, 143 144 455 456 O
within 145 151 457 463 O
1 152 153 464 465 B-upper_bound
week 154 158 466 470 I-upper_bound
prior 159 164 471 476 I-upper_bound
to 165 167 477 479 O
enrollment 168 178 480 490 O

Known 0 5 491 496 O
inherited 6 15 497 506 O
bleeding 16 24 507 515 B-chronic_disease
disorder 25 33 516 524 I-chronic_disease
or 34 36 525 527 O
coagulopathy 37 49 528 540 B-chronic_disease

Liver 0 5 541 546 B-chronic_disease
dysfunction 6 17 547 558 I-chronic_disease
manifested 18 28 559 569 O
by 29 31 570 572 O
SGTP 32 36 573 577 B-clinical_variable
( 37 38 578 579 I-clinical_variable
ALT 38 41 579 582 I-clinical_variable
) 41 42 582 583 I-clinical_variable
> 43 44 584 585 O
5X 45 47 586 588 B-lower_bound
Upper 48 53 589 594 B-clinical_variable
limit 54 59 595 600 I-clinical_variable
of 60 62 601 603 I-clinical_variable
normal 63 69 604 610 I-clinical_variable
( 70 71 611 612 I-clinical_variable
ULN 71 74 612 615 I-clinical_variable
) 74 75 615 616 I-clinical_variable
and/or 76 82 617 623 O
Aspartate 83 92 624 633 B-clinical_variable
aminotransferase 93 109 634 650 I-clinical_variable
( 110 111 651 652 I-clinical_variable
AST 111 114 652 655 I-clinical_variable
) 114 115 655 656 I-clinical_variable
> 116 117 657 658 O
5 117 118 658 659 B-lower_bound
X 119 120 660 661 I-lower_bound
ULN 121 124 662 665 O
and/or 125 131 666 672 O
direct 132 138 673 679 B-clinical_variable
( 139 140 680 681 I-clinical_variable
conjugated 140 150 681 691 I-clinical_variable
) 150 151 691 692 I-clinical_variable
bilirubin 152 161 693 702 I-clinical_variable
> 162 163 703 704 O
2X 164 166 705 707 B-lower_bound
ULN 167 170 708 711 O

Major 0 5 712 717 B-treatment
surgery 6 13 718 725 I-treatment
[ 14 15 726 727 O
excluding 15 24 727 736 O
Central 25 32 737 744 B-treatment
Venous 33 39 745 751 I-treatment
Access 40 46 752 758 I-treatment
Device 47 53 759 765 I-treatment
( 54 55 766 767 I-treatment
CVAD 55 59 767 771 I-treatment
) 59 60 771 772 I-treatment
replacement 61 72 773 784 I-treatment
and 73 76 785 788 O
bone 77 81 789 793 B-treatment
marrow 82 88 794 800 I-treatment
aspiration 89 99 801 811 I-treatment
and 100 103 812 815 O
non 104 107 816 819 B-treatment
- 107 108 819 820 I-treatment
open 108 112 820 824 I-treatment
biopsy 113 119 825 831 I-treatment
] 119 120 831 832 O
within 121 127 833 839 O
the 128 131 840 843 O
last 132 136 844 848 B-upper_bound
7 137 138 849 850 I-upper_bound
days 139 143 851 855 I-upper_bound
prior 144 149 856 861 I-upper_bound
to 150 152 862 864 O
enrollment 153 163 865 875 O
that 164 168 876 880 O
may 169 172 881 884 O
be 173 175 885 887 O
associated 176 186 888 898 O
with 187 191 899 903 O
a 192 193 904 905 O
risk 194 198 906 910 O
of 199 201 911 913 O
bleeding 202 210 914 922 O

Males 0 5 923 928 B-gender

New 0 3 929 932 O
diagnosis 4 13 933 942 O
of 14 16 943 945 O
de 17 19 946 948 B-cancer
novo 20 24 949 953 I-cancer
ALL 25 28 954 957 I-cancer
, 28 29 957 958 O
lymphomas 30 39 959 968 B-cancer
( 40 41 969 970 I-cancer
T 41 42 970 971 I-cancer
or 43 45 972 974 I-cancer
B 46 47 975 976 I-cancer
cell 48 52 977 981 I-cancer
) 52 53 981 982 I-cancer
, 53 54 982 983 O
or 55 57 984 986 O
mixed 58 63 987 992 B-cancer
- 63 64 992 993 I-cancer
phenotype 64 73 993 1002 I-cancer
acute 74 79 1003 1008 I-cancer
leukemia 80 88 1009 1017 I-cancer

Open 0 4 1018 1022 B-treatment
biopsy 5 11 1023 1029 I-treatment
is 12 14 1030 1032 O
considered 15 25 1033 1043 O
a 26 27 1044 1045 O
major 28 33 1046 1051 B-treatment
surgery 34 41 1052 1059 I-treatment

Planned 0 7 1060 1067 O
3 8 9 1068 1069 B-lower_bound
- 9 10 1069 1070 O
4 10 11 1070 1071 B-upper_bound
drug 12 16 1072 1076 I-upper_bound
systemic 17 25 1077 1085 O
induction 26 35 1086 1095 O
chemotherapy 36 48 1096 1108 B-treatment
with 49 53 1109 1113 O
a 54 55 1114 1115 O
corticosteroid 56 70 1116 1130 B-treatment
, 70 71 1130 1131 O
vincristine 72 83 1132 1143 B-treatment
and 84 87 1144 1147 O
a 88 89 1148 1149 O
single 90 96 1150 1156 O
dose 97 101 1157 1161 O
or 102 104 1162 1164 O
multiple 105 113 1165 1173 O
doses 114 119 1174 1179 O
of 120 122 1180 1182 O
asparaginase 123 135 1183 1195 B-treatment
, 135 136 1195 1196 O
with 137 141 1197 1201 O
or 142 144 1202 1204 O
without 145 152 1205 1212 O
daunorubicin 153 165 1213 1225 B-treatment

Prior 0 5 1226 1231 O
history 6 13 1232 1239 O
of 14 16 1240 1242 O
documented 17 27 1243 1253 O
DVT 28 31 1254 1257 B-chronic_disease
or 32 34 1258 1260 O
PE 35 37 1261 1263 B-chronic_disease
in 38 40 1264 1266 O
the 41 44 1267 1270 O
past 45 49 1271 1275 B-upper_bound
3 50 51 1276 1277 I-upper_bound
months 52 58 1278 1284 I-upper_bound

Renal 0 5 1285 1290 B-clinical_variable
function 6 14 1291 1299 I-clinical_variable
< 15 16 1300 1301 O
30 17 19 1302 1304 B-upper_bound
% 19 20 1304 1305 I-upper_bound
of 21 23 1306 1308 O
normal 24 30 1309 1315 O
for 31 34 1316 1319 O
age 35 38 1320 1323 O
and 39 42 1324 1327 O
size 43 47 1328 1332 O
as 48 50 1333 1335 O
determined 51 61 1336 1346 O
by 62 64 1347 1349 O
the 65 68 1350 1353 O
Schwartz 69 77 1354 1362 O
formula 78 85 1363 1370 O

Severe 0 6 1371 1377 O
hypertension 7 19 1378 1390 B-chronic_disease
is 20 22 1391 1393 O
defined 23 30 1394 1401 O
as 31 33 1402 1404 O
a 34 35 1405 1406 O
systolic 36 44 1407 1415 B-clinical_variable
or 45 47 1416 1418 O
diastolic 48 57 1419 1428 B-clinical_variable
blood 58 63 1429 1434 I-clinical_variable
pressure 64 72 1435 1443 I-clinical_variable
( 73 74 1444 1445 I-clinical_variable
BP 74 76 1445 1447 I-clinical_variable
) 76 77 1447 1448 I-clinical_variable
> 78 79 1449 1450 O
5 80 81 1451 1452 B-lower_bound
mm 82 84 1453 1455 I-lower_bound
Hg 85 87 1456 1458 I-lower_bound
above 88 93 1459 1464 O
the 94 97 1465 1468 O
95th 98 102 1469 1473 B-lower_bound
percentile 103 113 1474 1484 I-lower_bound
as 114 116 1485 1487 O
defined 117 124 1488 1495 O
by 125 127 1496 1498 O
the 128 131 1499 1502 O
National 132 140 1503 1511 O
High 141 145 1512 1516 O
Blood 146 151 1517 1522 O
Pressure 152 160 1523 1531 O
Education 161 170 1532 1541 O
Program 171 178 1542 1549 O
Working 179 186 1550 1557 O
Group 187 192 1558 1563 O
( 193 194 1564 1565 O
NHBPEP 194 200 1565 1571 O
) 200 201 1571 1572 O
established 202 213 1573 1584 O
guidelines 214 224 1585 1595 O
for 225 228 1596 1599 O
the 229 232 1600 1603 O
definition 233 243 1604 1614 O
of 244 246 1615 1617 O
normal 247 253 1618 1624 O
and 254 257 1625 1628 O
elevated 258 266 1629 1637 O
blood 267 272 1638 1643 O
pressure 273 281 1644 1652 O
in 282 284 1653 1655 O
children 285 293 1656 1664 O

Subjects 0 8 1665 1673 O
scheduled 9 18 1674 1683 O
to 19 21 1684 1686 O
have 22 26 1687 1691 O
> 27 28 1692 1693 O
3 29 30 1694 1695 B-lower_bound
Lumbar 31 37 1696 1702 O
Punctures 38 47 1703 1712 O
over 48 52 1713 1717 O
the 53 56 1718 1721 O
course 57 63 1722 1728 O
of 64 66 1729 1731 O
the 67 70 1732 1735 O
study 71 76 1736 1741 O
treatment 77 86 1742 1751 B-treatment
period 87 93 1752 1758 O

Uncontrolled 0 12 1759 1771 B-chronic_disease
severe 13 19 1772 1778 I-chronic_disease
hypertension 20 32 1779 1791 I-chronic_disease
at 33 35 1792 1794 O
enrollment 36 46 1795 1805 O

age 0 3 1806 1809 B-age
1 4 5 1810 1811 B-lower_bound
year(365 6 14 1812 1820 I-lower_bound
days 15 19 1821 1825 I-lower_bound
) 19 20 1825 1826 I-lower_bound
to 21 23 1827 1829 O
< 24 25 1830 1831 O
18 26 28 1832 1834 B-upper_bound
( 29 30 1835 1836 O
17 30 32 1836 1838 B-lower_bound
years 33 38 1839 1844 I-lower_bound
and 39 42 1845 1848 O
364 43 46 1849 1852 B-upper_bound
days 47 51 1853 1857 I-upper_bound
) 51 52 1857 1858 O
years 53 58 1859 1864 O

females 0 7 1865 1872 B-gender

